H. Lundbeck, Interim report for the three months ended 31 March 2004

- Cipralex® sales amounted to DKK 352 million in, up 350% from DKK 78 million in the year-earlier period.

- Ebixa® sales amounted to DKK 141 million, representing a 386% increase from DKK 29 million in the year-earlier period.

- In the first quarter of 2004, Lundbeck's portfolio of new products accounted for 45% of revenue relative to 19% in the year-earlier period. During the past 12 months, Lundbeck's reliance on mature drugs fell from 78% to 53% of revenue.